Pathology Watch

Deal Snapshot

Company: PathologyWatch

Website: www.pathologywatch.com

Sector / Category: Digital pathology / dermatopathology workflow / diagnostics platform

Headquarters: Salt Lake City, Utah

Founded: 2017

Investor: Frazier VC

Investment Vehicle: Series B

Deal Type: Primary investment

Company Overview

PathologyWatch provides an end-to-end digital dermatopathology platform that digitizes skin biopsy workflows, integrates with clinic EMRs, and supports remote review of digital slides. The company positions its technology around faster turnaround, streamlined clinic-to-lab workflows, and the application of AI to dermatopathology diagnostics.

Public Funding / Capital Events

May 12, 2020 — $5M Series A PathologyWatch announced a $5 million Series A led by SpringTide Investments and Rock Creek Capital, with additional participation from individual investors.

Nov 15–16, 2021 — $25M Series B PathologyWatch announced a $25 million Series B to expand its digital dermatopathology footprint, add lab capacity, and continue AI-driven diagnostics research. The company listed participants including Ceros Capital Markets, Rock Creek Capital, SpringTide, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group, and existing investors.

Nov 16, 2023 — Acquisition agreement announced (Sonic Healthcare) Sonic Healthcare announced it signed binding agreements to acquire Pathology Watch for a stated purchase price of US$130 million (cash and debt free), with closing expected in December 2023.

Investment Summary

Frazier VC invested in PathologyWatch through a primary Series B investment in November 2021.

Why We Invested

PathologyWatch operates in a workflow-critical diagnostic category where digitization can materially improve speed, consistency, and scalability. Its differentiation comes from delivering an integrated, end-to-end platform that connects lab systems, digital viewing, and EMR interfacing in a single clinical workflow, which increases adoption and switching costs once deployed. The model also benefits from growing demand for remote pathology workflows and the long-term potential for AI-enabled diagnostics layered on top of digital slide infrastructure.

Other Investors

Ceros Capital Markets

Rock Creek Capital

SpringTide Investments

Spark Growth Ventures

Blueprint Health

Blackbrook Management Group